Rajesh Kumar
Stock Analyst at HSBC
(2.83)
# 1,908
Out of 5,090 analysts
27
Total ratings
52.94%
Success rate
8.32%
Average return
Main Sectors:
Stocks Rated by Rajesh Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Downgrades: Hold | n/a | $47.86 | - | 3 | Nov 24, 2025 | |
| IQV IQVIA Holdings | Upgrades: Buy | $195 → $235 | $225.85 | +4.05% | 2 | Oct 9, 2025 | |
| ABBV AbbVie | Downgrades: Hold | n/a | $226.08 | - | 4 | Oct 1, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Hold | $675 → $700 | $1,010.31 | -30.71% | 3 | Aug 27, 2025 | |
| KDP Keurig Dr Pepper | Upgrades: Buy | $36 → $42 | $28.69 | +46.39% | 1 | Apr 25, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $660 → $670 | $572.77 | +16.98% | 3 | Apr 30, 2024 | |
| DHR Danaher | Upgrades: Buy | $250 → $280 | $226.25 | +23.76% | 2 | Apr 17, 2024 | |
| UNH UnitedHealth Group | Upgrades: Hold | $460 | $330.91 | +39.01% | 2 | Apr 4, 2024 | |
| TEVA Teva Pharmaceutical Industries | Initiates: Buy | $13 | $28.46 | -54.32% | 1 | Dec 18, 2023 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Hold | $55 → $53 | $52.15 | +1.63% | 2 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Reduce | $97 | $27.70 | +250.18% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $124 | $96.25 | +28.83% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $26.03 | +92.09% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $123 | $99.72 | +23.35% | 1 | Jul 14, 2023 |
Novo Nordisk
Nov 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $47.86
Upside: -
IQVIA Holdings
Oct 9, 2025
Upgrades: Buy
Price Target: $195 → $235
Current: $225.85
Upside: +4.05%
AbbVie
Oct 1, 2025
Downgrades: Hold
Price Target: n/a
Current: $226.08
Upside: -
Eli Lilly and Company
Aug 27, 2025
Upgrades: Hold
Price Target: $675 → $700
Current: $1,010.31
Upside: -30.71%
Keurig Dr Pepper
Apr 25, 2025
Upgrades: Buy
Price Target: $36 → $42
Current: $28.69
Upside: +46.39%
Thermo Fisher Scientific
Apr 30, 2024
Maintains: Buy
Price Target: $660 → $670
Current: $572.77
Upside: +16.98%
Danaher
Apr 17, 2024
Upgrades: Buy
Price Target: $250 → $280
Current: $226.25
Upside: +23.76%
UnitedHealth Group
Apr 4, 2024
Upgrades: Hold
Price Target: $460
Current: $330.91
Upside: +39.01%
Teva Pharmaceutical Industries
Dec 18, 2023
Initiates: Buy
Price Target: $13
Current: $28.46
Upside: -54.32%
Bristol-Myers Squibb Company
Oct 27, 2023
Upgrades: Hold
Price Target: $55 → $53
Current: $52.15
Upside: +1.63%
Jul 14, 2023
Initiates: Reduce
Price Target: $97
Current: $27.70
Upside: +250.18%
Jul 14, 2023
Initiates: Buy
Price Target: $124
Current: $96.25
Upside: +28.83%
Jul 14, 2023
Initiates: Buy
Price Target: $50
Current: $26.03
Upside: +92.09%
Jul 14, 2023
Initiates: Hold
Price Target: $123
Current: $99.72
Upside: +23.35%